MARKITTA BROWN: Open Payments
NPI 1992157002 · LONDON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$550 in 31 payments from 12 companies in 2025. Trend: 2023 $533 · 2024 $704 · 2025 $550
Food & beverage: $550
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $88 |
| Teva Pharmaceuticals USA, Inc. | 4 | $77 |
| Vanda Pharmaceuticals Inc. | 4 | $75 |
| Indivior Inc. | 4 | $73 |
| E.R. Squibb & Sons, L.L.C. | 3 | $44 |
| ABBVIE INC. | 3 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Lundbeck LLC | 2 | $34 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| Braeburn Inc. | 1 | $22 |
Products named: REXULTI, SUBLOCADE, AUSTEDO XR, COBENFY, VRAYLAR, HETLIOZ, FANAPT, CAPLYTA.
Industry payments across KY — which companies pay providers there.
